Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Ovarian Cancer
Related studies linked through entity extraction aliases.
Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Risk of Ovarian Cancer in Patients With a Pelvic Mass
- Status
- COMPLETED
- Phase
- N/A
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy
- Status
- COMPLETED
- Phase
- PHASE3
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
- Status
- UNKNOWN
- Phase
- PHASE2
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
- Status
- TERMINATED
- Phase
- PHASE1
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
- Status
- COMPLETED
- Phase
- PHASE2
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer
- Status
- COMPLETED
- Phase
- N/A
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
- Status
- COMPLETED
- Phase
- NA
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
- Status
- COMPLETED
- Phase
- NA
CT-2106 for the Second Line Treatment of Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
- Status
- TERMINATED
- Phase
- N/A
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.
- Status
- TERMINATED
- Phase
- NA